Published in final edited form as:

Cancer Res. 2007 January 1; 67(1): 425–426.

The terminology issue for myeloid-derived suppressor cells

Dmitry I. Gabrilovich¹, Vincenzo Bronte², Shu-Hsia Chen³, Mario P Colombo⁴, Augusto Ochoa⁵, Suzanne Ostrand-Rosenberg⁶, and Hans Schreiber⁷

¹ H. Lee Moffitt Cancer Center and University of South Florida, Tampa, FL, USA

² Istituto Oncologico Veneto, Padova, Italy,

³ Department Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY, USA

⁴ Immunotherapy & Gene Therapy Unit, Department of Experimental Oncology Istituto Nazionale Tumori, Milan, Italy

⁵ Stanley S. Scott Cancer Center, Louisiana State University Health Science Center, New Orleans, LA, USA

⁶ University of Maryland Baltimore County (UMBC), Baltimore, MD, USA

⁷ Department of Pathology, The University of Chicago, Chicago, IL, USA

To the Editor

The recent study by Yang R et al. (1) described antigen specific immune suppression by Gr-1⁺CD11b⁺ myeloid cells, which was mediated by the expression of CD80. This report continued series of recent papers published in Cancer Research, which provided strong evidence in support of critical role of these cells in tumor progression (1-6). Recent years have witnessed increasing interest in immunosuppressive cells of myeloid origin. During the last 18 months alone, more than 50 papers have appeared in peer-reviewed journals on this subject. Accumulation of these cells has been reported under pathological conditions including bacterial and parasitic infections, acute and chronic inflammation, and traumatic stress. However, most of the attention has been focused on the role of these cells in cancer. Immunosuppressive myeloid cells accumulate in large numbers in tumor-bearing mice, in practically all tested experimental models, as well as in patients with breast, lung, prostate, kidney, head and neck and other types of cancer. These cells are produced in response to a variety of tumor-derived cytokines and are a heterogeneous mixture of myeloid cells at different stages of differentiation. The precise nature of the suppressor cell population (i.e. precursors of granulocytes, macrophages, dendritic cells or early myeloid progenitors) depends on the hosts' tumor and tumor-derived factors. Despite this heterogeneity, immunosuppressive myeloid cells share some common characteristics: lack or reduced expression of markers of mature myeloid cells, expression of both Gr-1 and CD11b molecules in mice, inability to differentiate into mature myeloid cells in the presence of tumor-derived factors, high levels of reactive oxygen species, and activation of arginase I and other molecules. Most importantly, these cells possess a high potential to suppress immune responses *in vitro* and *in vivo*. Immunosuppressive myeloid cells are now considered by many a critical mechanism of tumor escape, as well as an important immunosuppressive factor for other pathological conditions.

Because these cells play a key role in regulation of immunity we feel it necessary to address one issue that causes confusion in this field. These cells lack a clear, unified name. In the literature, these cells have been called “immature myeloid cells” or “myeloid suppressor cells”. Although both of these names reflect the cells' biology, neither term is entirely accurate. The name “immature myeloid cells” implies that these cells are normal myeloid precursors. However, this may not be the case. Recent studies have demonstrated clear differences in the biology of normal immature myeloid cells and the cells that accumulate in tumor-bearing hosts. In addition, this term does not reflect the most important feature of these cells: their ability to suppress immune responses. The name “myeloid suppressor cells” (MSC) implies that these

cells include populations of mature myeloid cells, such as macrophages or dendritic cells, capable of displaying some immunosuppressive features under certain circumstances. However, this name is also not accurate, being too generic and potentially misleading since these cells are not mature myeloid cells. In addition, the abbreviation “MSC” is commonly used for the characterization of mesenchymal stem cells. We believe that the lack of an accurate name for these cells creates confusion and hampers attempts to develop a cohesive picture of the mechanisms of immune suppression in cancer and other pathological conditions.

Therefore, we suggest that these cells be called “myeloid-derived suppressor cells” (MDSC). We believe this term more closely reflects the origin and function of these cells and hope that it will stimulate further scientific discussions and progress not only in immunology but also in cancer biology where undoubtedly the same or similar cell populations play a major functional role.

References

1. Yang R, Cai Z, Zhang Y, Yutzy WHt, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. *Cancer Res* 2006;66:6807–15. [PubMed: 16818658]
2. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. *Cancer Res* 2006;66:1123–31. [PubMed: 16424049]
3. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. *Cancer Res* 2005;65:3044–8. [PubMed: 15833831]
4. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sefti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. *Cancer Res* 2005;65:9525–35. [PubMed: 16230418]
5. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. *Cancer Res*. September 15;2006 in press
6. Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. *Cancer Res* 2005;65:11743–51. [PubMed: 16357187]